Ivosidenib for IDH1-mutated cancers with liver or kidney issues
Treatments studied
Part of Cancer clinical trials.
This trial tests an oral drug (ivosidenib) for people with IDH1-mutated cancers who also have liver or kidney problems. It aims to find the right dose and see how safe and effective it is for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a cancer (like certain blood cancers or solid tumors) with an IDH1 R132 mutation
- You have moderate to severe liver problems or severe kidney problems
- Your kidney function (creatinine clearance) is at least 60 mL/min if you have liver problems, or between 15 and 29 mL/min if you have severe kidney problems
- Your liver function tests (bilirubin, AST, etc.) are within certain ranges based on your group
- You have not had a stem cell transplant in the last 60 days, or active GVHD requiring treatment
- You agree to use effective birth control if you could become pregnant or father a child
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests CPX-351 together with ivosidenib in people with IDH1-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to improve disease control, especially in tumors with a specific genetic change called IDH1.
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
Hear when a new IDH1-Mutated Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.